Prevalence and the role of CCR5 Delta 32 heterozygosity in disease progression in HIV positive patients in the Czech Republic

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064211%3A_____%2F19%3AW0002034" target="_blank" >RIV/00064211:_____/19:W0002034 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/19:43919682 RIV/75010330:_____/19:00012682

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pubmed/31914779/" target="_blank" >https://www.ncbi.nlm.nih.gov/pubmed/31914779/</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Prevalence and the role of CCR5 Delta 32 heterozygosity in disease progression in HIV positive patients in the Czech Republic

Popis výsledku v původním jazyce

Background: Entry of human immunodeficiency virus type 1 (HIV-1) in target cells is enabled by CD4 receptor and one of two co-receptors, CXCR4 or CCR5. Deletion of 32 bp in CCRS gene (CCR5 Delta 32) in both alleles provides strong but not absolute resistance to HIV-1 infection and deletion in one allele slows disease progression to AIDS. Here, we analyzed the prevalence and the role of CCR5 Delta 32 heterozygosity on the disease progression in HIV positive patients in the Czech Republic. Patients and methods: A total of 92 HIV-1 seropositive subjects that included 80 Czech individuals from the AIDS center in the Hospital Na Bulovce in Prague were enrolled in CCR5 genotyping as a part of a study of the role of HIV fitness on disease progression. DNA was extracted from patient's peripheral blood mononuclear cells and subjected to real-time PCR with specific probes detecting wild-type and 32 bp-deleted CCR5 variants. A subgroup of 74 antiretroviral therapy-naive patients with more than one year or follow-up was used to determine the role of the CCR5 Delta 32 heterozygous phenotype in disease progression. Results: CCR5 Delta 32 was found heterozygous in 23.8% of 80 Czech HIV-1 seropositive individuals which is very similar to 21% and 24% prevalence reported in HIV negative Czech population. Homozygous mutant variant was not detected. In CCR5 Delta 32 heterozygous group we observed slightly higher mean CD4(+) T-cell count and lower mean plasma viremia levels. Conclusions: Ovorall, our study indicates no obvious benefit of CCRS Delta 32 heterozygosity on HIV transmission and only small benefit on disease progression in the Czech HIV-1 cohort.

Název v anglickém jazyce

Prevalence and the role of CCR5 Delta 32 heterozygosity in disease progression in HIV positive patients in the Czech Republic

Popis výsledku anglicky

Background: Entry of human immunodeficiency virus type 1 (HIV-1) in target cells is enabled by CD4 receptor and one of two co-receptors, CXCR4 or CCR5. Deletion of 32 bp in CCRS gene (CCR5 Delta 32) in both alleles provides strong but not absolute resistance to HIV-1 infection and deletion in one allele slows disease progression to AIDS. Here, we analyzed the prevalence and the role of CCR5 Delta 32 heterozygosity on the disease progression in HIV positive patients in the Czech Republic. Patients and methods: A total of 92 HIV-1 seropositive subjects that included 80 Czech individuals from the AIDS center in the Hospital Na Bulovce in Prague were enrolled in CCR5 genotyping as a part of a study of the role of HIV fitness on disease progression. DNA was extracted from patient's peripheral blood mononuclear cells and subjected to real-time PCR with specific probes detecting wild-type and 32 bp-deleted CCR5 variants. A subgroup of 74 antiretroviral therapy-naive patients with more than one year or follow-up was used to determine the role of the CCR5 Delta 32 heterozygous phenotype in disease progression. Results: CCR5 Delta 32 was found heterozygous in 23.8% of 80 Czech HIV-1 seropositive individuals which is very similar to 21% and 24% prevalence reported in HIV negative Czech population. Homozygous mutant variant was not detected. In CCR5 Delta 32 heterozygous group we observed slightly higher mean CD4(+) T-cell count and lower mean plasma viremia levels. Conclusions: Ovorall, our study indicates no obvious benefit of CCRS Delta 32 heterozygosity on HIV transmission and only small benefit on disease progression in the Czech HIV-1 cohort.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE

ISSN

1210-7913

e-ISSN

—

Svazek periodika

68

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

138-143

Kód UT WoS článku

000510476800004

EID výsledku v databázi Scopus

2-s2.0-85077700665